<DOC>
	<DOC>NCT02709850</DOC>
	<brief_summary>The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial hypercholesterolemia.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<criteria>Inclusion Criteria for All Cohorts: Must have given written informed consent and be able to comply with all study requirements Males or females 18 to 65 years, inclusive, at the time of informed consent BMI ≤ 35.0 kg/m2 Females must be nonpregnant and nonlactating, and either surgically sterile or postmenopausal. Males must be surgically sterile, abstinent or using an acceptable contraceptive method Inclusion Criteria for Cohorts A to D and Cohorts AA to DD Only: Fasting TG &gt; 150 mg/dL at Screening Fasting LDLC &gt; 70 mg/dL at Screening Inclusion Criteria for Cohort EE Only: Homozygous FH diagnosis and fasting LDLC ≥ 190 mg/dL (4.9 mmol/L) Inclusion Criteria for Cohort FF Only: Heterozygous FH diagnosis and fasting LDLC ≥ 160 mg/dL (4.1 mmol/L) Inclusion Criteria for Cohorts EE and FF Only: Maximally tolerated stable LDLC lowering agents (stable for at least 12 weeks) On stable lowfat diet Stable weight (± 4 kg) for ≥ 6 weeks prior to screening Exclusion Criteria for All Cohorts: Known history or positive test for HIV, HCV, or HBV Treatment with another Study Drug, biological agent, or device within onemonth or 5halflives of screening Regular use of alcohol within 6 months of screening Use of concomitant drugs unless authorized by the Sponsor Medical Monitor Known contraindication and/or allergy to heparin Smoking &gt; 10 cigarettes a day Considered unsuitable for inclusion by the Principal Investigator Exclusion Criteria for Cohorts EE and FF: Myocardial infarction, percutaneous transluminal coronary intervention, or coronary artery bypass graft surgery within 12 weeks prior to screening, or cerebrovascular accident within 24 weeks prior to screening. Subjects with adequately treated stable angina, per Investigator assessment, may be included Congestive heart failure defined by NYHA Classes III or IV T2DM with HbA1c &gt; 8.0% Prior treatment with gene therapy Currently receiving apheresis treatments or last apheresis treatment was within 8 weeks of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ANGPTL-3</keyword>
</DOC>